SEC Form 4 · accession 0001209191-18-055804
KYNTRA BIO, INC. · KYNB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kalevi Kurkijarvi
Director
Period of report
Oct 18, 2018
Accepted (ET)
Oct 19, 2018 · 8:40 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000921299
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Oct 18, 2018 | M | 4,000 | $2.90 | A | 27,700 | D | |
| Common StockF2 | Oct 18, 2018 | S | 250 | $53.88 | D | 27,450 | D | |
| Common StockF3 | Oct 18, 2018 | S | 3,750 | $55.52 | D | 23,700 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F4 | $2.90 | Oct 18, 2018 | M | 4,000 | D | — | Jun 24, 2020 | Common Stock | 4,000 | 4,000 | D |
Explanation of responses
- F1Shares sold pursuant to a 10b5-1 plan.
- F2The shares were sold at prices ranging from $53.87 to $53.885. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F3The shares were sold at prices ranging from $55.06 to $55.81. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F4Fully vested.